KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cme Group (CME) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Cme Group (CME) over the last 16 years, with Dec 2024 value amounting to $2.9 billion.

  • Cme Group's Cash & Equivalents rose 5.37% to $2.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 billion, marking a year-over-year increase of 5.37%. This contributed to the annual value of $2.9 billion for FY2024, which is 0.67% down from last year.
  • Latest data reveals that Cme Group reported Cash & Equivalents of $2.9 billion as of FY2024, which was down 0.67% from $2.9 billion recorded in FY2023.
  • Cme Group's 5-year Cash & Equivalents high stood at $2.9 billion for FY2023, and its period low was $1.6 billion during FY2020.
  • In the last 3 years, Cme Group's Cash & Equivalents had a median value of $2.9 billion in 2024 and averaged $2.8 billion.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 73.58% in 2021, then fell by 4.05% in 2022.
  • Over the past 5 years, Cme Group's Cash & Equivalents (Yearly) stood at $1.6 billion in 2020, then spiked by 73.58% to $2.8 billion in 2021, then decreased by 4.05% to $2.7 billion in 2022, then climbed by 7.05% to $2.9 billion in 2023, then fell by 0.67% to $2.9 billion in 2024.